Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript
Source: SeekingAlpha
2025-11-12 13:11:31 ET
Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases November 12, 2025 9:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Hansa Biopharma AB (publ) (HNSBF) Discusses Phase III Trial Data and Developments in IgG-Cleaving Platform for Kidney Transplantation and Autoimmune Diseases Transcript
Hansa Biopharma AB
NASDAQ: HNSBF
HNSBF Trading
-85.0% G/L:
$2.91 Last:
28,750 Volume:
$2.91 Open:
HNSBF Latest News
September 24, 2025 02:06:00 pm
Imlifidase successfully meets primary endpoint in pivotal US Phase 3 ConfIdeS trial in kidney transplantation
